Kinetic analysis of antagonist-occupied adenosine-A3 receptors within membrane microdomains of individual cells provides evidence of receptor dimerization and allosterism

FASEB Journal

Volumn 28, Issue 10, 2014, Pages 4211-4222

  Corriden, Ross ^a,c   Kilpatrick, Laura E ^a   Kellam, Barrie ^b   Briddon, Stephen J ^a   Hill, Stephen J ^a  

^a QUEEN S MEDICAL CENTRE   (United Kingdom)

^b UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^c UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

Dissociation; Fluorescence correlation spectroscopy; Fluorescent ligand; GPCR

Indexed keywords

8 [4 (2 AMINOETHYLCARBAMOYL)METHOXYPHENYL] 1,3 DIPROPYLXANTHINE; 9 CHLORO 2 (2 FURYL) 5 PHENYLACETYLAMINO 1,2,4 TRIAZOLO[1,5 C]QUINAZOLINE; ADENOSINE A3 RECEPTOR; ADENOSINE A3 RECEPTOR ANTAGONIST; CA 200645; GREEN FLUORESCENT PROTEIN; UNCLASSIFIED DRUG; PROTEIN BINDING;

ALLOSTERISM; ARTICLE; BINDING AFFINITY; CELL MEMBRANE; CONTROLLED STUDY; DIMERIZATION; DRUG ANTAGONISM; DRUG BINDING; DRUG DIFFUSION; FLUORESCENCE CORRELATION SPECTROSCOPY; HUMAN; HUMAN CELL; RECEPTOR BINDING; ANIMAL; CHO CELL LINE; CRICETULUS; HAMSTER; KINETICS; METABOLISM; PROTEIN MULTIMERIZATION;

ADENOSINE A3 RECEPTOR ANTAGONISTS; ALLOSTERIC REGULATION; ANIMALS; CHO CELLS; CRICETINAE; CRICETULUS; HUMANS; KINETICS; MEMBRANE MICRODOMAINS; PROTEIN BINDING; PROTEIN MULTIMERIZATION; RECEPTOR, ADENOSINE A3;

EID: 84907692805     PISSN: 08926638     EISSN: 15306860     Source Type: Journal    
DOI: 10.1096/fj.13-247270     Document Type: Article

References (46)

1. Fredholm, B. F., Ijzerman, A. P., Jacobson, K. A., Linden, J., and Muller, C. E. (2011) International Union of Basic and Clinical Pharmacology. LXXXI: nomenclature and classification of adenosine receptors: an update. Pharmacol. Rev. 63, 1-34
2. Hill, S. J., May, L. T., Kellam, B., and Woolard, J. (2014) Allosteric interactions at adenosine A1 and A3 receptors: new insights into the role of small molecules and receptor dimerization. Br. J. Pharmacol. 171, 1102-1113
3. Bar-Yehuda, S., Luger, D., Ochaion, A., Cohen, S., Patokaa, R., Zozulya, G., Silver, P. D., de Morales, J. M., Caspi, R. R., and Fishman, P. (2011) Inhibition of experimental auto-immune uveitis by the A3 adenosine receptor agonists CF101. Int. J. Mol. Med. 28, 727-731
4. Cohen, S., Stemmer, S. M., Zozulya, G., Ochaion, A., Patoka, R., Barer, F., Bar-Yehuda, S., Rath-Wolfson, L., Jacobson, K. A., and Fischman, P. (2011) CF102 an A3 adenosine receptor agonist mediates anti-tumor and anti-inflammatory effects in the liver. J. Cell. Physiol. 226, 2438-2447
5. Muller, C. E., and Jacobson, K. A. (2011) Recent developments in adenosine receptor ligands and their potential as novel drugs. Biochim. Biophys. Acta 1808, 1290-1308
6. Albrecht-Kupper, B. E., Leineweber, K., and Nell, P. G. (2012) Partial adenosine A1-receptor agonists for cardiovascular therapies. Purinergic Signal. 8, S91-S99
7. Tendera, M., Gaszekewska-Zurek, E., Parma, Z., Ponikowski, P., Jankowska, E., Kawecka-Jaszcz, M., Czarnecka, D., Krzeminska- Pakula, M., Bedmrkiewicz, Z., Sosnowski, M., Kilama, M. O., and Agrawal, R. (2012) The new oral adenosine A1 receptor agonist capadenoson in male patients with stable angina. Clin. Res. Cardiol. 101, 585-591
8. Corriden, R., Self, T., Akong-Moore, K., Nizet, V., Kellam, B., Briddon, S. J., and Hill, S. J. (2013) Adenosine A3 receptors in neutrophil microdomains promote the formation of bacteriatethering cytonemes. EMBO Rep. 14, 726-732
9. Chen, Y., Corriden, R., Inoue, Y., Yip, L., Hashiguchi, N., Zinhemagel, A., Nizet, V., Insel, P. A., and Junger, W. G. (2006) ATP release guides neutrophil chemotaxis via P2Y2 and A3 receptors. Science 314, 1792-1795
10. Corriden, R., and Insel, P. A. (2012) New insights regarding the regulation of chemotaxis by nucleotides, adenosine and their receptors. Purinergic Signal. 8, 587-598
11. Gines, S., Ciruela, F., Burgueno, J., Casado, V., Canela, E. I., Mallol, J., Luis, C., and Franco, R. (2001) Involvement of caveolae in ligand-induced recruitment and internalization of A1-adenosine receptor and adenine deaminase in an epithelial cell line. Mol. Pharmacol. 59, 1314-1323
12. Ostrom, R. S., and Insel, P. A. (2004) The evolving role of lipid rafts and caveolae in G protein-coupled signalling: implications for molecular pharmacology. Br. J. Pharmacol. 143, 235-245
13. Insel, P. A., Head, B. P., Ostrom, R. S., Patel, H. H., Swaney, J. S., Tang, C. M., and Roth, D. M. (2005) Caveolae and lipid rafts: G protein-coupled receptor signalling microdomains in cardiac myocytes. Ann. N. Y. Acad. Sci. 1047, 166-172
14. Cordeaux, Y., Briddon, S. J., Alexander, S. P. H., Kellam, B., and Hill, S. J. (2008) Agonist-occupied A3-adenosine receptors exist within heterogeneous complexes in membrane microdomains of individual living cells. FASEB J. 22, 850-860
15. Azzi, M., Charest, P. G., Angers, S., Rousseau, G., Kohout, T., Bouvier, M., and Pineyro, G. (2003) Beta-arrestin-mediated activation of MPAK by inverse agonists reveals distinct active conformations for G protein-coupled receptors. Proc. Natl. Acad. Sci. U. S. A. 100, 11406-11411
16. Baker, J. G., Hall, I. P., and Hill, S. J. (2003) Agonist and inverse agonist actions of "β-blockers" at the human β2-adrenoceptor provide evidence for agonist-directed signalling. Mol. Pharmacol. 64, 1357-1369
17. Kenakin, T. P. (2012) Biased signalling and allosteric machines: new vistas and challenges for drug discovery. Br. J. Pharmacol. 165, 1659-1669
18. Whalen, E. J., Rajagopal, S., and Lefkowitz, R. J. (2011) Therapeutic potential of β-arrestin and G protein-biased agonists. Trends Mol. Med. 17, 126-139
19. Katritch, V., Cherezov, V., and Stevens, R. C. (2013) Structurefunction of the G protein-coupled receptor superfamily. Annu. Rev. Pharmacol. Toxicol. 53, 531-556
20. Venkatakrishnan, A. J., Deupi, X., Lenon, G., Tate, C. G., Schertler, G. F., and Babu, M. M. (2013) Molecular signatures of G-protein-coupled receptors. Nature 494, 185-194
21. May, L. T., Leach, K., Sexton, P. M., and Christopoulos, A. (2007) Allosteric modulation of G protein-coupled receptors. Annu. Rev. Pharmacol. Toxicol. 47, 1-51
22. Keov, P., Sexton, P. N., and Christopoulos, A. (2010) Allosteric modulation of G protein-coupled receptors: a pharmacological perspective. Neuropharmacology 60, 24-35
23. Briddon, S. J., Middleton, R. J., Cordeaux, Y., Flavin, F. M., Weinstein, J. A., George, M. W., Kellam, B., and Hill, S. J. (2004) Quantitative analysis of the formation and diffusion of A1-adenosine receptor-antagonist complexes in living cells. Proc. Natl. Acad. Sci. U. S. A. 101, 4673-4678
24. Middleton, R. J., Briddon, S. J., Cordeaux, Y., Yates, A. S., Dale, C. L., George, M. W., Baker, J. G., Hill, S. J., and Kellam, B. (2007) New fluorescent adenosine A1-receptor agonists that allow quantification of ligand-receptor interactions in microdomains of single living cells. J. Med. Chem. 50, 782-793
25. Baker, J.G., Adams, L., Salchow, K., Mistry, S., Middleton, R., Hill, S. J., and Kellam, B. (2011) Synthesis and characterization of high-affinity 4,4-difluoro-4-bora-3a,4a-diaza-s-indacene (BODIPY)-labeled fluorescent ligands for human beta-adrenoceptors. J. Med. Chem. 54, 6874-6887
26. Vernall, A. J., Hill, S. J., and Kellam, B. (2013) The evolving small-molecule fluorescent-conjugate toolbox for class A GPCRs. Br. J. Pharmacol. 171, 1073-1084
27. Stoddart, L. A., Vernall, A. J., Denman, J. L., Briddon, S. J., Kellam, B., and Hill, S. J. (2012) Fragment screening at adenosine A3-receptors in living cells using a fluorescence-based binding assay. Chem. Biol. 19, 1105-1115
28. May, L. T., Briddon, S. J., and Hill, S. J. (2010) Antagonist selective modulation of adenosine A1 and A3 receptor pharmacology by the food dye Brilliant Black BN: evidence for allosteric interactions. Mol. Pharmacol. 77, 678-686
29. May, L. T., Self, T. J., Briddon, S. J., and Hill, S. J. (2010) The effect of allosteric modulators on the kinetics of agonist-G protein-coupled receptor interactions in single living cells. Mol. Pharmacol. 78, 511-523
30. May, L. T., Bridge, L. J., Stoddart, L. A., Briddon, S. J., and Hill, S. J. (2011) Allosteric interactions across native adenosine-A3 receptor homodimers: quantification using single cell ligand binding kinetics. FASEB J. 25, 3465-3476
31. Briddon, S. J., and Hill, S. J. (2007) Pharmacology under the microscope: the use of fluorescence correlation spectroscopy to determine the properties of ligand-receptor complexes. Trends Pharmacol. Sci. 28, 637-645
32. Briddon, S. J., Middleton, R. J., Yates, A. S., George, M. W., Kellam, B., and Hill, S. J. (2004) Application of fluorescence correlation spectroscopy to the measurement of agonist binding to a G-protein coupled receptor at the single cell level. Faraday Discuss. 126, 197-207
33. Briddon, S. J., Gandía, J., Amaral, O. B., Ferré, S., Lluís, C., Franco, R., Hill, S. J., and Ciruela, F. (2008) Plasma membrane diffusion of G protein-coupled receptor oligomers. Biochim. Biophys. Acta 1783, 2262-2268
34. Briddon, S.J., Hern, J. A., and Hill, S. J. (2010) Use of fluorescence correlation spectroscopy to study GPCRs. In G Protein Coupled Receptors: Essential Methods (Poyner, D. E. and Wheatley, M., eds) pp. 169-196, Wiley-Blackwell, West Sussex, UK.
35. Gao, Z. G., Van Muijlwijk-Koezen, J. E., Chen, A., Muller, C. E., Ijzerman, A. P., and Jacobson, K. A. (2001) Allosteric modulation of A3 adenosine receptors by a series of 3-(2-pyridinyl)isoquinoline derivatives. Mol. Pharmacol. 60, 1057-1063
36. Clark, E. A., and Hill, S. J. (1995) Differential effect of sodium ions and guanine nucleotides on the binding of thioperamide and clobenpropit to histamine H3-receptors in rat cerebral cortical membranes. Br. J. Pharmacol. 114, 357-362
37. Hugo Gutierrez-de-Tera, H., Massink, A., Rodríguez, D., Liu, W., Won Han, G., Joseph, J. S., Katritch, I., Heitman, L. H., Xia, L., IJzerman, A. P., Cherezov, V., Vsevolod Katritch, V., and Stevens, R. C. (2013) The role of a sodium ion binding site in the allosteric modulation of the A2A adenosine G protein-coupled receptor. Structure 21, 1-11
38. Lefkowitz, R. J., Cotecchia, S., Samama, P., and Costa, T. (1993) Constitutive activity of receptors coupled to guanine nucleotide regulatory proteins. Trends Pharmacol. Sci. 14, 303-307
39. Samama, P., Cotecchia, S., Costa, T., and Lefkowitz, R. J. (1995) A mutation-induced activated state of the β-adrenergic receptor: extending the ternary complex model. J. Biol. Chem. 268, 4625-4636
40. Samama, P., Pel, G., Costa, T., Cotecchia, S., and Lefkowitz, R. J. (1993) Negative antagonists promote an inactive conformation of the β2-adrenergic receptor. Mol. Pharmacol. 45, 390-294
41. Bridge, L. J., King, J. R., Hill, S. J., and Owen, M. R. (2010) Mathematical modelling of signalling in a two-ligand G-protein coupled receptor system: agonist-antagonist competition. Math. Biosci. 223, 115-132
42. Gao, Z. G., Kim, S. K., Gross, A. S., Chen, A., Blaustein, J. B., and Jacobson, K. A. (2003) Identification of essential residues involved in the allosteric modulation of the human A3 adenosine receptor. Mol. Pharmacol. 63, 1021-1031
43. Sykes, D. A., Parry, C., Reilly, J., Wright, P., Fairhurst, R. A., and Charlton, S. J. (2014) Observed drug-receptor association rates are governed by membrane affinity: the importance of establishing "micro-pharmacokinetic/pharmacodynamic relationships" at the β2-adrenoceptor. Mol. Pharmacol. 85, 608-617
44. Vauquelin, G. V., and Charlton, S. J. (2010) Long-lasting target binding and rebinding as mechanisms to prolong in vivo drug action. Br. J. Pharmacol. 161, 488-508
45. Vauquelin, G. V. (2010) Rebinding: or why drugs may act longer in vivo than expected from their in vitro target residence time. Expert Opin. Drug Discov. 5, 927-941
46. Tuommino, P. J., and Copeland, R. A. (2008) Residence time of receptor-ligand complexes and its effect on biological function. Biochemistry 47, 5481-5492